Wallich R, Kramer M D, Simon M M
Institut für Immunologie und Serologie, Universität Heidelberg, Germany.
Behring Inst Mitt. 1994 Dec(95):106-8.
We are studying processes leading to protective immunity in murine Lyme borreliosis in order to derive a suitable vaccine candidate for clinical use. Our work focuses on the role of the two main outer surface lipoproteins A and B (OspA and OspB) of the causative agent of Lyme disease, the spirochete Borrelia burgdorferi, as targets for its specific elimination. We could show that native and recombinant LipOspA induce monospecific immune sera able to passively transfer protection in SCID mice against experimental and tick-borne infection and disease. Recent results for phase I and II safety and efficacy trails are promising in demonstrating that the recombinant LipOspA vaccine candidate is safe and immunogenic and elicits borreliacidal antibodies.
我们正在研究鼠类莱姆病中产生保护性免疫的过程，以便获得一种适合临床使用的候选疫苗。我们的工作重点是莱姆病病原体——螺旋体伯氏疏螺旋体的两种主要外表面脂蛋白A和B（OspA和OspB）作为特异性清除靶点的作用。我们能够证明，天然和重组脂蛋白OspA可诱导单特异性免疫血清，这种血清能够在SCID小鼠中被动转移针对实验性感染和蜱传感染及疾病的保护作用。I期和II期安全性和有效性试验的最新结果表明，重组脂蛋白OspA候选疫苗是安全且具有免疫原性的，并能引发杀伯氏疏螺旋体抗体，前景乐观。
